Literature DB >> 1636090

Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major.

P A Bretscher1, G Wei, J N Menon, H Bielefeldt-Ohmann.   

Abstract

Cell-mediated, but not antibody-mediated, immune responses protect humans against certain pathogens that produce chronic diseases such as leishmaniasis. Effective vaccination against such pathogens must therefore produce an immunological "imprint" so that stable, cell-mediated immunity is induced in all individuals after natural infection. BALB/c mice "innately susceptible" to Leishmania major produce antibodies after substantial infection. In the present study, "susceptible" mice injected with a small number of parasites mounted a cell-mediated response and acquired resistance to a larger, normally pathogenic, challenge. This vaccination strategy may be applicable in diseases in which protection is dependent on cell-mediated immunity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1636090     DOI: 10.1126/science.1636090

Source DB:  PubMed          Journal:  Science        ISSN: 0036-8075            Impact factor:   47.728


  130 in total

Review 1.  The molecular basis of T cell differentiation.

Authors:  R A Flavell
Journal:  Immunol Res       Date:  1999       Impact factor: 2.829

2.  Evolution of lesion formation, parasitic load, immune response, and reservoir potential in C57BL/6 mice following high- and low-dose challenge with Leishmania major.

Authors:  R Lira; M Doherty; G Modi; D Sacks
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

3.  Altering the cellular location of an antigen expressed by a DNA-based vaccine modulates the immune response.

Authors:  P J Lewis; L A Babiuk
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

4.  T lymphocyte immunity in host defence against Chlamydia trachomatis and its implication for vaccine development.

Authors:  X Yang; R Brunham
Journal:  Can J Infect Dis       Date:  1998-03

5.  Antinuclear autoantibodies (ANA) in Gulf War-related illness and chronic fatigue syndrome (CFS) patients.

Authors:  A Skowera; E Stewart; E T Davis; A J Cleare; C Unwin; L Hull; K Ismail; G Hossain; S C Wessely; M Peakman
Journal:  Clin Exp Immunol       Date:  2002-08       Impact factor: 4.330

6.  Leishmania tropica infection, in comparison to Leishmania major, induces lower delayed type hypersensitivity in BALB/c mice.

Authors:  Hamid Mahmoudzadeh-Niknam; Simin Sadat Kiaei; Davood Iravani
Journal:  Korean J Parasitol       Date:  2007-06       Impact factor: 1.341

7.  Depletion of interleukin-4 in BALB/c mice with established Leishmania major infections increases the efficacy of antimony therapy and promotes Th1-like responses.

Authors:  G S Nabors; J P Farrell
Journal:  Infect Immun       Date:  1994-12       Impact factor: 3.441

8.  Development of a safe live Leishmania vaccine line by gene replacement.

Authors:  R G Titus; F J Gueiros-Filho; L A de Freitas; S M Beverley
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

9.  Characterization of the B-cell immune response elicited in BALB/c mice challenged with Neospora caninum tachyzoites.

Authors:  Luzia Teixeira; Andreia Marques; Carla Sofia Meireles; Ana Rita Seabra; Diana Rodrigues; Pedro Madureira; Augusto M R Faustino; Carolina Silva; Adília Ribeiro; Paula Ferreira; José Manuel Correia da Costa; Nuno Canada; Manuel Vilanova
Journal:  Immunology       Date:  2005-09       Impact factor: 7.397

10.  B cells are required for the switch from Th1- to Th2-regulated immune responses to Plasmodium chabaudi chabaudi infection.

Authors:  A W Taylor-Robinson; R S Phillips
Journal:  Infect Immun       Date:  1994-06       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.